NT0102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)

Last updated: December 18, 2017
Sponsor: Neos Therapeutics, Inc
Overall Status: Completed

Phase

3

Condition

Williams Syndrome

Autism

Tourette's Syndrome

Treatment

N/A

Clinical Study ID

NCT01835548
NT0102.1004
  • Ages 6-12
  • All Genders

Study Summary

This is a randomized, double-blind, placebo-controlled, parallel group, Phase 3 trial to evaluate the safety and efficacy of NT0102 in the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in pediatric patients 6 to 12 years of age in a laboratory classroom study.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Currently being treated for ADHD

Exclusion

Exclusion Criteria:

  • Other psychiatric diagnoses

  • Significant cognitive impairment

  • Chronic medical illnesses

  • Structural cardiac defects

  • Significant abnormal lab tests

  • Taking disallowed medications

  • Positive drug test

Study Design

Total Participants: 87
Study Start date:
July 01, 2013
Estimated Completion Date:
July 31, 2014

Connect with a study center

  • Florida Clinical Research Center

    Bradenton, Florida 34208
    United States

    Site Not Available

  • Florida Clinical Research Center

    Maitland, Florida 32751
    United States

    Site Not Available

  • Center for Psychiatry and Behavioral Medicine

    Las Vegas, Nevada 89128
    United States

    Site Not Available

  • Duke University

    Durham, North Carolina 27705
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.